End-Stage Renal Disease (ESRD) Market to Grow at 12.7% CAGR by 2030 | North America Leads with 38% Share | Key Players: B. Braun, Baxter, Medtronic, Fresenius, Nipro, Asahi Kasei

End-Stage Renal Disease (ESRD) Market Overview

The Global End-Stage Renal Disease (ESRD) Market is projected to grow at a CAGR of 12.7% during the forecast period 2023-2030, driven by the rising prevalence of chronic kidney disorders, growing geriatric population, and increasing demand for renal replacement therapies. ESRD represents the final, most severe stage of chronic kidney disease (CKD), where the kidneys lose nearly all functional capacity, necessitating dialysis or kidney transplantation for survival. The market is witnessing significant growth due to advancements in dialysis technologies, increased awareness of renal disease management, and improvements in healthcare infrastructure across developing nations. Additionally, the growing incidence of diabetes and hypertension, which are leading causes of kidney failure, is further fueling the demand for ESRD treatments.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/end-stage-renal-disease-market?Juli

Recent Developments:

✅ January 2026: A leading renal care device manufacturer launched a next‐generation portable hemodialysis system with enhanced blood purification efficiency and improved patient comfort for home‐based therapy.

✅ November 2025: A major pharmaceutical company announced positive Phase III results for a novel nephroprotective biologic that reduces progression rates of kidney failure in patients with advanced chronic kidney disease, potentially delaying the need for dialysis.

✅ September 2025: A global healthcare technology firm introduced an AI‐enabled renal health monitoring platform that integrates wearable sensors and cloud analytics to track patient vitals and optimize dialysis scheduling.

✅ June 2025: A consortium of dialysis clinics partnered with a telehealth provider to offer remote ESRD patient management and virtual consultation services, improving adherence to treatment protocols and reducing hospital visits.

✅ March 2025: A major renal nutrition and support solutions company expanded its portfolio with specialized renal dietary supplements designed to support electrolyte balance and nutritional needs in ESRD patients undergoing dialysis.

Mergers & Acquisitions:

✅ January 2026: A leading global renal care provider acquired a home dialysis solutions specialist, expanding its portfolio of portable and patient‐centric dialysis devices.

✅ October 2025: A major pharmaceutical company completed the acquisition of a biotech firm focused on kidney disease therapeutics, strengthening its presence in CKD and ESRD treatment pipelines.

✅ August 2025: A healthcare technology company merged with a digital patient monitoring platform developer to integrate AI‐driven analytics and remote management tools for ESRD patients.

✅ May 2025: A large medical device manufacturer acquired a dialysis consumables supplier, enhancing its supply chain and product offerings for hemodialysis and peritoneal dialysis clinics.

✅ March 2025: Two regional renal care service providers merged to form a larger integrated renal care network, optimizing operational efficiencies and expanding access to dialysis and supportive care services.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=end-stage-renal-disease-market?Juli

Key Players:

B. Braun Melsungen AG - Holds an estimated 16.2% share, driven by its comprehensive portfolio of hemodialysis machines, consumables, and integrated renal care solutions.

Baxter International Inc. - Holds around 15.5% share, supported by innovations in peritoneal dialysis systems, solutions, and home dialysis platforms.

Medtronic PLC - Holds approximately 14.1% share, fueled by advanced vascular access devices, renal monitoring systems, and minimally invasive therapies.

Fresenius SE & Co. KGaA - Holds a 13.8% share, driven by its global network of dialysis clinics, hemodialysis products, and integrated renal care services.

Nipro Corporation - Holds 9.7% share, supported by its high-quality dialysis equipment, bloodlines, and renal consumables for clinical and home care.

Asahi Kasei Medical Co. - Holds 8.4% share, fueled by innovations in dialysis membranes, filters, and biocompatible consumables.

Trivitron Healthcare - Holds 7.6% share, driven by its dialysis devices, monitoring systems, and healthcare service offerings in emerging markets.

Guangzhou MeCan Medical Limited - Holds 6.5% share, supported by affordable dialysis equipment and expansion in the Asia-Pacific region.

JMS North America Corporation - Holds 5.8% share, focused on peritoneal and hemodialysis systems for clinical and home settings.

NxStage Medical - Holds 6.4% share, driven by portable and home dialysis solutions that improve patient convenience and care outcomes.

Market Segmentation:

By Treatment & Diagnosis, the treatment segment dominates with around 72% share of the market, driven largely by the rising adoption of dialysis therapies. Within treatment, hemodialysis holds the largest share at 41%, followed by peritoneal dialysis at 21%, and emerging wearable artificial kidney devices at 10%, reflecting growing investment in patient-friendly and home-based solutions. Kidney transplantation accounts for roughly 15% of the treatment market, supported by advancements in immunosuppressive therapies and surgical procedures. The diagnostic segment contributes about 28%, with blood tests (12%), urine tests (9%), and imaging tests (7%) being widely used for early detection, monitoring of kidney function, and disease progression.

By End-User, hospitals and clinics hold the largest share of 58%, benefiting from established infrastructure, nephrology specialists, and access to advanced treatment modalities. Standalone dialysis centers account for 42%, reflecting the growth of specialized centers offering cost-effective, frequent dialysis services and home-care support. This segmentation underscores the critical role of both institutional and specialized care facilities in managing ESRD patients globally.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/end-stage-renal-disease-market?Juli

Regional Insights:

North America dominates the market with an estimated 38% share, driven by high prevalence of chronic kidney disease, advanced healthcare infrastructure, and widespread adoption of dialysis and renal care therapies. The United States accounts for the largest portion, supported by strong government reimbursement policies, technologically advanced dialysis systems, and initiatives to expand home-based dialysis.

Europe holds approximately 25% share, fueled by established healthcare systems, increasing geriatric populations, and supportive reimbursement frameworks in countries like Germany, France, and the UK. The market is further boosted by ongoing clinical research, adoption of innovative dialysis devices, and kidney transplant programs.

Asia-Pacific is expected to witness the fastest growth at a CAGR of over 14%, accounting for around 22% of the market by 2030. Rising prevalence of diabetes and hypertension, growing awareness of renal disorders, expanding healthcare infrastructure, and increasing availability of cost-effective dialysis services in countries such as India, China, and Japan are key growth drivers.

Latin America contributes roughly 10% of the market, supported by government initiatives to expand renal care facilities and rising investments in dialysis centers across Brazil, Mexico, and Argentina.

Market Dynamics:

Technological Advancements Driving Market Growth
Technological innovation in renal disease treatment is a key factor propelling the ESRD market. Chronic kidney failure, or end-stage renal disease, results in progressive loss of kidney function, often necessitating frequent dialysis sessions. Traditional dialysis is time-consuming, physically taxing, and carries inherent risks.

Innovative initiatives such as KidneyX, a public-private partnership between the US Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN), are accelerating research in kidney disease prevention, diagnosis, and treatment. One notable effort, The Kidney Project, led by Shuvo Roy, PhD (UC San Francisco) and William Fissell, MD (Vanderbilt University Medical Center), has successfully developed and preclinically tested a smartphone-sized artificial kidney device. This device integrates two critical components: a hemofilter, which removes waste and toxins, and a bioreactor, which simulates kidney functions such as blood electrolyte balancing. The artificial kidney aims to replicate and even improve upon the quality of life offered by kidney transplantation, the current "gold standard" in ESRD treatment.

Additionally, established players are advancing portable dialysis solutions. For instance, in March 2021, Baxter International Inc. received FDA clearance for its next-generation Artificial Kidney 98 dialysis machine, a compact, user-friendly system designed to facilitate home hemodialysis (HHD) treatments. Such technological innovations are expected to expand patient access, improve treatment outcomes, and reinforce the market's growth trajectory.

Risks and Challenges in Hemodialysis Limiting Market Expansion
Despite technological progress, risks associated with hemodialysis, particularly home-based or nocturnal treatments, may constrain market growth. Solo HHD patients face potential medical emergencies, including loss of consciousness, blood loss, or hypotension, which can be life-threatening without immediate assistance. Nocturnal therapy further increases risk due to longer treatment durations, reduced alertness, and delayed response to alarms during sleep.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.